Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China - Summary - MDSpire
Advertisement
Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China
To outline the clinical features and disease manifestations of juvenile systemic sclerosis (jSSc) and assess therapeutic responses over an 11-year period.
Key Findings:
Skin sclerosis was the predominant symptom in all patients (100.0%).
Antinuclear antibody (ANA) was positive in 76.2% of cases, with anti-ssDNA being the most common specific antibody (23.8%).
Significant reduction in overall disease severity (J4s) from 5.94 to 2.67 (P = 0.003) and skin involvement (mRSS) from 10.0 to 7.42 (P = 0.008) after treatment.
Fourteen patients received biologic therapies, with 11 treated with tocilizumab.
No fatalities or severe adverse events were reported during the follow-up.
Interpretation:
jSSc is a rare, severe multiorgan disorder in children, characterized by specific autoantibody profiles. The J4s and mRSS are effective tools for monitoring disease severity and treatment response.
Limitations:
Retrospective design may introduce bias.
Small sample size limits generalizability.
Conclusion:
Timely diagnosis and personalized treatment strategies, including tocilizumab, may improve clinical outcomes in pediatric jSSc.
So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.
Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.
